Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Mirjam de With

Showing results (11-20 of 17) with videos related to

Pageof 2
Sort By:
You have reached the last page of results.This site can display upto 17 results.
Clinical Pharmacology and Therapeutics|December 21, 2018
Influence of the Proton Pump Inhibitor Esomeprazole on the Bioavailability of Regorafenib: A Randomized Crossover Pharmacokinetic StudyFemke M de Man, Koen G A M Hussaarts, Mirjam de With, et al.
Journal of the National Comprehensive Cancer Network : JNCCN|June 11, 2026
Real-World Impact of UGT1A1 Genotype-Guided Irinotecan Dosing on Severe Toxicity and Hospitalization: A Multicenter StudyNiels Heersche, Sofía L J Peeters, Doortje Böhm, et al.
European Journal of Cancer (Oxford, England : 1990)|January 8, 2022
UGT1A1 genotype-guided dosing of irinotecan: A prospective safety and cost analysis in poor metaboliser patientsEmma C Hulshof, Mirjam de With, Femke M de Man, et al.
The Lancet Regional Health. Europe|March 4, 2026
Survival of patients with colorectal or pancreatic cancer who received <i>UGT1A1</i> genotype-guided dosing of irinotecan in the Netherlands (2017-2024): a retrospective, multicentre cohort studySofía L J Peeters, Niels Heersche, Doortje Böhm, et al.
Clinical Pharmacology and Therapeutics|April 9, 2022
Dihydropyrimidine Dehydrogenase Phenotyping Using Pretreatment Uracil: A Note of Caution Based on a Large Prospective Clinical StudyMirjam de With, Jonathan Knikman, Femke M de Man, et al.
Journal of Geriatric Oncology|April 3, 2026
Predictors of poor treatment tolerability in older patients receiving fluoropyrimidine-based chemotherapy: A prospective cohort studyJoosje C Baltussen, Jonathan E Knikman, Nienke A de Glas, et al.
European Journal of Cancer (Oxford, England : 1990)|June 4, 2025
Dose-individualisation of fluoropyrimidines based on pre-treatment serum uracil levels: the Alpe2U studyJonathan E Knikman, Mirjam de With, Niels Heersche, et al.
Pageof 2

Showing results (11-20 of 17) with videos related to

Sort By:
Pageof 2
You have reached the last page of results.This site can display upto 17 results.
Clinical Pharmacology and Therapeutics|December 21, 2018
Influence of the Proton Pump Inhibitor Esomeprazole on the Bioavailability of Regorafenib: A Randomized Crossover Pharmacokinetic StudyFemke M de Man, Koen G A M Hussaarts, Mirjam de With, et al.
Journal of the National Comprehensive Cancer Network : JNCCN|June 11, 2026
Real-World Impact of UGT1A1 Genotype-Guided Irinotecan Dosing on Severe Toxicity and Hospitalization: A Multicenter StudyNiels Heersche, Sofía L J Peeters, Doortje Böhm, et al.
European Journal of Cancer (Oxford, England : 1990)|January 8, 2022
UGT1A1 genotype-guided dosing of irinotecan: A prospective safety and cost analysis in poor metaboliser patientsEmma C Hulshof, Mirjam de With, Femke M de Man, et al.
The Lancet Regional Health. Europe|March 4, 2026
Survival of patients with colorectal or pancreatic cancer who received <i>UGT1A1</i> genotype-guided dosing of irinotecan in the Netherlands (2017-2024): a retrospective, multicentre cohort studySofía L J Peeters, Niels Heersche, Doortje Böhm, et al.
Clinical Pharmacology and Therapeutics|April 9, 2022
Dihydropyrimidine Dehydrogenase Phenotyping Using Pretreatment Uracil: A Note of Caution Based on a Large Prospective Clinical StudyMirjam de With, Jonathan Knikman, Femke M de Man, et al.
Journal of Geriatric Oncology|April 3, 2026
Predictors of poor treatment tolerability in older patients receiving fluoropyrimidine-based chemotherapy: A prospective cohort studyJoosje C Baltussen, Jonathan E Knikman, Nienke A de Glas, et al.
European Journal of Cancer (Oxford, England : 1990)|June 4, 2025
Dose-individualisation of fluoropyrimidines based on pre-treatment serum uracil levels: the Alpe2U studyJonathan E Knikman, Mirjam de With, Niels Heersche, et al.
Pageof 2